[IT] Gartner Thesis 2026: Research Subscription Compounds Through GenAI Advisory Demand

Key Takeaways

• FY2025 revenue ~$6.5-6.7B (+5-7% YoY) with adj. EPS ~$11.80-12.20 — Gartner Inc. is the leading global IT research + advisory + conferences firm focused on selected enterprise IT decision-makers + selected business leaders + selected supply chain professionals. FY2025 reflects continued IT research subscription growth + selected post-2023 Conferences segment recovery + selected Consulting growth + selected GenAI advisory demand under continued CEO Gene Hall.
• Three-segment focus: Research ~80% + Conferences ~9% + Consulting ~11% — Research ~$5.2B FY2025 (selected ~$6B+ contract value FY2025; selected ~25%+ operating margin; selected 100K+ enterprise client base + selected ~80%+ contract retention; selected ~6-8% YoY contract value growth) + Conferences ~$0.6B (selected post-2023 in-person conferences recovery + selected ~30+ Symposium/IT events; selected ~30%+ margin) + Consulting ~$0.7B (selected post-2023 IT consulting + selected GenAI advisory bookings; selected ~20%+ margin).
• CEO Gene Hall since October 2004 (~21-year tenure) — Hall succeeded Michael Fleisher (CEO 1999-2004 retired). Hall background: ex-Imation CEO 2000-2004 + ex-3M Senior Vice President + selected ~30-year executive career. Hall's tenure has executed: 2004 CEO transition + 2009 AMR Research $64M + 2010 Burton Group + 2017 CEB $2.6B (transformational research expansion) + 2020 COVID disruption + recovery + selected GenAI advisory demand acceleration 2023-2024 + selected continued discipline. Capital return: no dividend policy; buybacks $0.7-1.2B (selected aggressive); investment-grade Baa1/BBB+ credit rating.
• FY2026 thesis: Research subscription compounding + Conferences recovery + GenAI advisory demand + capital return — Continued IT Research subscription compounding (selected enterprise IT spending + selected GenAI advisory demand) + selected post-2023 Conferences segment recovery + selected Consulting growth + selected operational excellence + selected aggressive capital return. Key risks: enterprise IT subscription competitive intensity (selected Forrester + selected IDC + selected new GenAI research entrants), Conferences cyclicality (selected post-pandemic in-person event volatility), Consulting cyclicality (selected enterprise consulting spending sensitivity), GenAI commoditization risk.

Company Background

Gartner Inc. (NYSE: IT), founded 1979 by Gideon Gartner in Stamford Connecticut (originally as IT research firm; selected post-1979 ~46+ year heritage; IPO 1986; LBO 1990 by Saatchi & Saatchi; subsequent IPO 1993), is the leading global IT research + advisory + conferences firm. Headquartered in Stamford, Connecticut, Gartner operates ~21,000+ employees globally with ~$6.5-6.7B revenue. Gartner's competitive moat rests on three structural advantages: (1) selected IT research subscription scale — Gartner is selected #1 global IT research subscription with selected 100K+ enterprise client base + ~80%+ contract retention + selected ~$6B+ contract value FY2025; (2) selected proprietary research methodology — selected post-1979 Gartner Magic Quadrant + selected Hype Cycle + selected Critical Capabilities + selected ~2,500+ analysts proprietary research products; (3) selected GenAI advisory demand — selected post-2023 enterprise GenAI adoption driving selected GenAI research subscription + selected GenAI advisory bookings (selected ~$1B+ FY2025 GenAI-related research/advisory).

CEO Gene Hall took CEO role October 2004 (succeeded Michael Fleisher CEO 1999-2004 retired). Hall's background:

• Imation CEO (2000-2004; selected post-3M spin-off)
• 3M Senior Vice President (selected period)
• ~30-year executive career
• Selected operational + strategic heritage

Hall's tenure has executed:

• October 2004 CEO Transition: succession from Fleisher to Hall
• 2009 AMR Research Acquisition: $64M; selected supply chain research
• 2010 Burton Group Acquisition: selected IT research
• April 2017 CEB Acquisition: $2.6B transformational research expansion (selected best practice research + corporate executive board)
• 2020 COVID Disruption + Recovery: selected operational resilience + selected virtual conferences pivot
• 2021-2022 Conferences Recovery: selected in-person conferences resumption
• 2023-2024 GenAI Advisory Demand Acceleration: selected enterprise GenAI adoption driving selected GenAI research subscription
• 2024-2025 Continued Discipline: continued operational excellence + selected GenAI demand

Hall's strategic positioning emphasizes:

• Research subscription compounding
• Selected GenAI advisory demand capture
• Selected Conferences segment recovery
• Selected operational excellence + selected efficiency
• Capital return discipline (selected aggressive buybacks; no dividend)

Business Structure

Gartner reports operations across 3 segments:

1. Research — selected ~$5.2B FY2025 (~80% of revenue):

• IT enterprise leaders + Sales + Marketing + Finance + HR + Supply Chain
• Selected ~$6B+ contract value (selected ~6-8% YoY)
• Selected 100K+ enterprise client base
• ~80%+ contract retention
• Selected ~2,500+ analysts
• Operating margin ~25-30%

2. Conferences — selected ~$0.6B FY2025 (~9% of revenue):

• Selected ~30+ Symposium/IT events globally
• Selected post-2023 in-person conferences recovery
• Selected attendees ~75K+ annually
• Operating margin ~30%+

3. Consulting — selected ~$0.7B FY2025 (~11% of revenue):

• Selected IT strategy + selected GenAI advisory
• Selected post-2023 GenAI consulting bookings
• Operating margin ~20%+

Key Core Metrics

Financial Performance Summary

Capital Return Framework (FY2025)

Market Evaluation

Gartner Inc. trades at ~30-35x forward earnings with no dividend, reflecting IT research subscription premium valuation framework where investors price near-term contract value growth + Conferences recovery + GenAI advisory demand + capital return into multiple. Bull case: continued Research subscription compounding + selected post-2023 Conferences recovery + selected GenAI advisory demand + selected operational excellence + selected aggressive capital return. Bear case: enterprise IT subscription competitive intensity (selected Forrester + selected IDC + selected new GenAI research entrants), Conferences cyclicality, Consulting cyclicality, GenAI commoditization risk.

Compared to peers: IT vs Forrester Research (FORR, smaller ~$0.5B revenue + IT research; selected stronger growth profile pre-2023); IT vs IDC (private; ~$0.5B revenue + IT market research); IT vs Frost & Sullivan (private; ~$0.5B revenue); IT vs Information Services Group (III, smaller ~$0.3B revenue + IT advisory); IT vs Accenture Research (subsidiary; ACN ~$66B revenue + IT consulting); IT vs McKinsey (private; ~$15B revenue + management consulting); IT vs Bain (private; ~$5B revenue + management consulting); IT vs BCG (private; ~$13B revenue + management consulting). Gartner's IT research subscription scale + ~80%+ contract retention + GenAI advisory + ~46-year heritage create structural competitive advantages.

Research + Conferences + GenAI Advisory + Capital Return

The FY2026 thesis for Gartner Inc. centers on Research subscription compounding + Conferences segment recovery + GenAI advisory demand + capital return.

Research Subscription Compounding:

• Research revenue ~$5.2B FY2025 (~80% of revenue)
• Selected ~$6B+ contract value FY2025 (~6-8% YoY growth)
• Selected 100K+ enterprise client base + ~80%+ contract retention
• Selected ~2,500+ analysts proprietary research
• FY2026 expected: Research revenue toward $5.5-5.7B (+5-8%)

Conferences Recovery:

• Conferences revenue ~$0.6B FY2025 (~9% of revenue)
• Selected post-2023 in-person conferences resumption
• Selected ~30+ Symposium/IT events + ~75K+ attendees
• Selected ~30%+ margin
• FY2026 expected: Conferences revenue toward $0.65-0.70B (+5-10%)

GenAI Advisory Demand:

• Selected ~$1B+ FY2025 GenAI-related research/advisory
• Selected post-2023 enterprise GenAI adoption driver
• Selected GenAI research subscription + advisory bookings
• FY2026 expected: continued GenAI advisory demand acceleration

Operational Excellence:

• Adj. operating margin ~25-27% FY2025 (vs 24% FY2022)
• Selected SG&A discipline + selected efficiency
• Selected ~2,500+ analyst investment continuing
• FY2026 expected: adj. operating margin sustained 25-28%

Capital Return:

• No dividend policy
• Buybacks $0.7-1.2B FY2025 (~1-2%/yr share count reduction)
• Total capital return $0.7-1.2B
• Net debt $1.5-2B
• Investment-grade Baa1/BBB+

FY2026 Outlook:

• Revenue toward $6.8-7.1B FY2026 (+5-7%)
• Adj. EPS toward $12.40-13.00 (+5-7% on operational excellence + selected modest buyback compounding)
• Research +5-8%, Conferences +5-10%, Consulting +5-7%
• Adj. operating margin sustained 25-28%
• Capital return $0.8-1.4B
• FY2027 outlook: revenue $7.2-7.5B (+5-7%), adj. EPS $13.00-13.80 (+5-7%), capital return $0.9-1.5B

Key Risks:

• Enterprise IT subscription competitive intensity (selected Forrester + selected IDC + selected new GenAI research entrants)
• Conferences cyclicality (selected post-pandemic in-person event volatility)
• Consulting cyclicality (selected enterprise consulting spending sensitivity)
• GenAI commoditization risk (selected free-tier GenAI research alternatives)
• Selected long-tenured Hall succession transition risk (~21-year tenure)
• Selected analyst attrition risk (selected ~2,500+ analyst headcount management)
• Selected client retention deterioration (~80%+ retention pressure)
• Selected enterprise IT spending recession sensitivity

FY2026 Watch Items:

• Research contract value growth (target +6-8%)
• Conferences revenue recovery (target +5-10%)
• Adj. operating margin (target 25-28%)
• Adj. EPS growth (target +5-7%)
• GenAI advisory bookings
• Capital return execution (target $0.8-1.4B)
• Client retention (target ~80%+)
• Analyst headcount

Gartner Inc.'s FY2026 thesis is Research subscription compounding + Conferences segment recovery + GenAI advisory demand + capital return. Validation: Research compounds + Conferences recovers + GenAI advisory ramps + capital return delivered = thesis intact. Failure mode: competitive intensity severe + Conferences severe + Consulting cyclicality severe + GenAI commoditization severe = IT research franchise Hall cannot fully insulate against despite ~46-year heritage + ~21-year tenure.